Share
Regulation formalised a distinction already visible in several large companies' portfolios. Since then, sales panels, search behaviour and brand portfolios have begun describing different slices of what used to look like one market..
***
ON 21 JANUARY 2026, Kenvue took an established brand and cut it in half. ORSL, the name it had spent years building, was reserved for a WHO-formula product for diarrhoeal dehydration, in powder and ready-to-drink formats. A second brand, eRZL, was created for everyday hydration and positioned against heat exhaustion, muscle cramps and tiredness.
The new architecture maps almost exactly on to the line the regulator had drawn. Three months earlier, on 14 October 2025, FSSAI withdrew every permission that had allowed food-licensed products to carry the term "ORS" in their branding. The Delhi High Court declined to block the orders on 31 October, and a national enforcement directive to states followed in November. Genuine medicinal ORS, licensed as a drug and made to the recognised WHO formula, keeps the term. Food products that had used it now had to find new names.
What has happened since is that three visible signals from this market have started describing different things.
PharmaTrac's ORS sales are contracting
PharmaTrac, which audits pharmaceutical sales through a stockist panel, shows the ORS market shrinking. March 2026 sales fell to ₹85 crore from ₹115 crore a year earlier, a fall of 26 per cent, with sales over the preceding 12 months down 8 per cent to ₹1,128 crore. Electral, the FDC brand that has long led the category, saw its 12-month sales value fall 7 per cent.
The tempting reading is that the ban did this. PharmaTrac is more careful, noting that the fall has to be read against an unusually strong prior year and normal seasonal patterns. FDC's FY26 results add company context, naming Electral alongside Zifi and Enerzal among several subdued top brands.
Search favours "ORS" and "electrolyte" over "hydration"
In the week beginning 12 October, which included FSSAI's 14 October order, search interest in "ORS drink" rose 65 per cent. "ORS powder" was almost flat that week and rose 28 per cent the following week. Google Trends' two-year data surfaced one item in the Rising list for "ORS drink": "ors drink banned".
Beyond that spike, search still runs on clinical and functional language. "ORS powder" draws an estimated 74,000 average monthly searches, ahead of "electrolyte powder" at 60,500, and "electrolyte powder" outdraws "hydration powder" by roughly 46 times. One telling association: people searching "ORS drink" also frequently searched "energy drink" and "ors energy drink", more often than "electrolyte drink" and far more often than "diarrhea".
This establishes what language is salient, not what anyone bought, and it does not demonstrate continuity from before the ban. Many of those ORS searches may be people seeking precisely what the regulation protects: a therapeutic product still entitled to the name.
The brands were already moving
The everyday-hydration push did not begin in October 2025. Cipla was describing the entire beverage industry as Prolyte's addressable market in November 2024. Reliance entered the category with RasKik Gluco Energy at ₹10 in January 2025, and HUL brought Liquid I.V. to India that April.
FSSAI did not set off this activity. It formalised a distinction that several large companies were already drawing, and converted it from a marketing choice into a labelling requirement.
Why the three signals do not meet
Consider March 2026, the month PharmaTrac recorded sales value down 26 per cent. Search interest in "ORS powder" that same month ran about 12 per cent higher than a year earlier, and across the March-to-May peak it ran 27 per cent higher, touching a two-year high in mid-May. Higher relative interest in one query and lower recorded ORS sales can both be accurate. They are not describing the same thing.
These signals should not be forced into one chart. PharmaTrac's ORS series is built from pharmaceutical stockist sales; search records queries, not purchases; and products such as eRZL, RasKik and Liquid I.V. sit across food, wellness and retail channels. Public methodology does not show how renamed electrolyte foods are classified within the ORS series, or how much of their sales it captures.
That makes reclassification and channel movement plausible explanations for part of the recorded decline, alongside the strong prior year, seasonality and genuine demand loss. The figures cannot say how much came from each. The practical problem is when that number stands in for the wider hydration opportunity: it describes a narrower, medically defined slice at exactly the moment the broader category is being redrawn.
Renaming also creates a less visible task. eRZL can draw on Kenvue's distribution and visibly echoes ORSL, but the company cannot assume the old name's search behaviour will transfer. Among the terms tested, the strongest candidate for a generic bridge is "electrolyte", which already attracts substantial search; "hydration" remains far smaller. Rebuilding discoverability is a strategic risk this dataset cannot yet price.
Each signal answers a different question. The commercial error would be to treat any one of them as the market.
The Numbers
74,000 | Estimated average monthly Indian searches for "ORS powder", the largest of the nine category terms examined
60,500 | The same measure for "electrolyte powder"
46x | "Electrolyte powder", at an estimated 60,500 monthly searches, against "hydration powder" at 1,300. Generic "hydration" vocabulary remains far smaller
+12% | Search interest in "ORS powder", March 2026 against March 2025
−26% | Fall in ORS sales value in the same month, year on year, per PharmaTrac. Read against an unusually strong prior year and normal seasonality
₹1,128 cr | ORS market sales over the 12 months to March 2026, after an 8 per cent decline
−7% | Electral's 12-month sales value decline, despite being the compliant category leader
Method: Monthly search volumes are SEMrush India, database updated August 2026, estimated average monthly volume over the preceding twelve months, a window that is predominantly but not entirely post-ban. Movement over time is Google Trends, India, weekly, August 2024 to August 2026, which reports relative search interest indexed within each comparison, not volume; its "rising" lists compare the period with the preceding equivalent period. Bare "ORS" and bare "electrolyte" were excluded as ambiguous, the first mixing in AIIMS patient-portal traffic and the second school chemistry, in favour of more specific terms. SEMrush figures estimate monthly queries; Google Trends figures index relative search interest. Neither measures individual people or purchases, and overlapping terms have not been summed. The nine SEMrush terms examined were: electrolyte drink, electrolyte powder, hydration drink, hydration powder, sports drink, ORS drink, ORS powder, zero sugar electrolyte drink, zero sugar electrolyte powder. Sales figures are PharmaTrac as reported by the Economic Times, and FDC's audited FY26 results.
What This Means For Brands
• Do not treat ORS data as a stand-in for the entire hydration opportunity. First establish which products and channels the series captures before treating contraction as lost consumer demand.
• "Electrolyte" is the strongest bridge candidate among the terms tested. Generic searches using "hydration" remain far smaller; brands should not rely on lifestyle vocabulary alone.
• Treat renaming as a brand-building investment. Do not assume a successor name inherits its predecessor's search equity; measure branded search, referral traffic and repeat purchase before attempting to price the loss.
